Biotech 2050 Podcast

Biotech 2050 Podcast

Biotech2050 Podcast is a think tank chronicling the disruptions changing the biotech industry over the next 50 years.

Denne podkasten er hentet fra en åpen RSS-feed og er ikke publisert av Podme. Den kan derfor inneholde annonser.

Episoder(261)

116. Retinal restoration and visions for growth, Brian Culley, CEO, Lineage Cell Therapeutics

116. Retinal restoration and visions for growth, Brian Culley, CEO, Lineage Cell Therapeutics

Mr. Culley joined Lineage as Chief Executive Officer in September 2018. Prior to joining Lineage, Mr. Culley served from August 2017 to September 2018 as interim Chief Executive Officer at Artemis The...

24 Aug 202217min

115. Innovations in diabetes therapies, Timothy Kieffer, CSO, Manasi Sinha Jaiman, CMO, ViaCyte

115. Innovations in diabetes therapies, Timothy Kieffer, CSO, Manasi Sinha Jaiman, CMO, ViaCyte

Timothy Kieffer Dr. Kieffer has a deep knowledge of gene and cell therapies, regenerative medicine, diabetes applied research, and industry experience. As Chief Scientific Officer, he leads ViaCyte’s ...

17 Aug 202218min

114. Advancing cell therapy and multiple myeloma treatment, Ying Huang, CEO, Legend Biotech

114. Advancing cell therapy and multiple myeloma treatment, Ying Huang, CEO, Legend Biotech

Dr. Ying Huang currently serves as Chief Executive Officer of Legend Biotech. He sits on the Board of Directors of Legend, as well as Quanta Therapeutics. Dr. Huang brings over 9 years of experience ...

10 Aug 202223min

113. Envisioning VDC cancer treatment, Elisabet de los Pinos, CEO, Aura Biosciences

113. Envisioning VDC cancer treatment, Elisabet de los Pinos, CEO, Aura Biosciences

Eli de los Pinos is the founding CEO of Aura, which she has created from the ground up: She developed the company concept and has spearheaded fundraising efforts, and today, she continues to lead Aura...

3 Aug 202220min

112. New approaches in CNS diseases, Brad Margus, Co-founder and Executive Chairman, Cerevance

112. New approaches in CNS diseases, Brad Margus, Co-founder and Executive Chairman, Cerevance

Brad Margus is co-founder and Executive Chairman of Cerevance, a drug discovery company advancing a robust pipeline of targeted treatments for patients with neurodegenerative diseases, including Parki...

27 Jul 202223min

111. Synthetic biology & probiotics, Aoife Brennan, President & CEO, Synlogic

111. Synthetic biology & probiotics, Aoife Brennan, President & CEO, Synlogic

Dr. Aoife Brennan is an experienced physician scientist and drug developer responsible for the successful clinical development and registration of multiple transformative medicines. Aoife has served a...

20 Jul 202230min

110. Novel cell and gene therapies, Mark Gergen, CEO, Poseida Therapeutics, Inc.

110. Novel cell and gene therapies, Mark Gergen, CEO, Poseida Therapeutics, Inc.

Mr. Gergen was appointed Chief Executive Officer of Poseida in February 2022. He joined Poseida in February 2018, initially serving as Chief Business Officer and Chief Financial Officer before being n...

13 Jul 202229min

109. Gene therapy CDMO, Tim Miller, CEO, Erandi De Silva, SVP of Prod. Dev., Forge Biologics

109. Gene therapy CDMO, Tim Miller, CEO, Erandi De Silva, SVP of Prod. Dev., Forge Biologics

Timothy J. Miller, Ph.D. CEO, President and Co-Founder Timothy Miller is CEO, President and Co-Founder of Forge Biologics, Inc., a VC-backed gene therapy development engine focused on accelerating ac...

29 Jun 202221min

Populært innen Vitenskap

fastlegen
tingenes-tilstand
jss
liberal-halvtime
rekommandert
forskningno
villmarksliv
sinnsyn
tomprat-med-gunnar-tjomlid
rss-kunstig-intelligens-med-elisabeth-maren-og-morten
fjellsportpodden
rss-rekommandert
vett-og-vitenskap-med-gaute-einevoll
dekodet-2
rss-nysgjerrige-norge
smart-forklart
nevropodden
diagnose
rss-paradigmepodden
abels-tarn